Upper limb fracture.
Conditions
Interventions
Intervention 1: Intervention group 1: Lidocaine (alone), 300 mg of 1.5% lidocaine solution. Intervention 2: Intervention group 2: Pethidine+Lidocaine, 300 mg of 1.5% lidocaine solution + 1 mg pethidin
Sponsors
Kermanshah University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Informed consent to participate in the study Age between 18 and 75 years Appropriate hemodynamic status (ASA I or II) Need for supraclavicular regional anesthesia for upper limb surgery No history of known drug sensitivity to the drugs used No neurological, muscular, or vascular problems in the target limb No substance abuse No coagulation disorders No need for blocks for both upper limbs
Exclusion criteria
Exclusion criteria: Patient dissatisfaction during the study Loss of consciousness during the procedure Severe neurological or nerve problems during the procedure History of upper limb numbness Dementia or Parkinson's disease Allergy to the medications used History of drug abuse or uncontrolled diabetes (due to possible effects on the nerves) Occurrence of coagulation disorders during the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Duration of pain relief. Timepoint: Monitoring of the level of analgesia and the effectiveness of the medication in the ward and operating room is performed every thirty minutes and will continue until the patient first needs painkillers. Method of measurement: Visual analog scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to onset of analgesia. Timepoint: Immediately after the injection into the nerve sheath is completed, the time of onset of analgesia will be measured and recorded using a stopwatch. Method of measurement: Stopwatch.;Hemodynamic monitoring. Timepoint: All patients were assessed for hemodynamic status (systolic and diastolic blood pressure, heart rate (HR), respiratory rate (RR), and blood oxygen saturation (SpO2)) before anesthesia. These vital signs will be monitored and recorded at baseline, 10 minutes after the end of the injection, and 30 minutes after the end of the injection. Method of measurement: Sphygmomanometer, pulse oximeter. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSeyyed Khashayar Molaei
Kermanshah University of Medical Sciences
Outcome results
None listed